<DOC>
	<DOCNO>NCT00920647</DOCNO>
	<brief_summary>Elaprase ( idursulfase ) , large molecular protein , expect cross blood brain barrier therapeutic level administer intravenously . A new formulation idursulfase , idursulfase-IT , differs intravenous ( IV ) formulation , Elaprase , develop suitable delivery cerebrospinal fluid ( CSF ) via intrathecal administration . This Phase I/II study design obtain necessary safety exposure data , well secondary exploratory outcome measure , interpret used design subsequent clinical trial .</brief_summary>
	<brief_title>A Safety Dose Ranging Study Idursulfase ( Intrathecal ) Administration Via Intrathecal Drug Delivery Device Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement Are Receiving Treatment With Elaprase®</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1a . A deficiency iduronate2sulfatase enzyme activity ≤10 % low limit normal range measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) AND 1b . A documented mutation iduronate2sulfatase gene OR A normal enzyme activity level one sulfatase measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) . 2 . The patient male ≥3 &lt; 18 year age . 3 . The patient evidence Screening early stage ( duration severity metric per protocol ) Hunter syndromerelated Central Nervous System ( CNS ) involvement , define : The patient Intelligence quotient ( IQ ) ≤77 OR There evidence change ≥1 ≤2 standard deviation decline previous protocoldefined neurodevelopmental assessment . The duration protocoldefined neurologic involvement least 3 month le 36 month document patient 's medical history . 4 . The patient receive tolerated minimum 6 month treatment weekly intravenous idursulfase , receive 80 % total planned infusion within time frame , include receive 100 % planned infusion within 4 week immediately precede surgical insertion IDDD . 5 . The patient must sufficient auditory capacity , without aid , complete require protocol testing , compliant wearing aid schedule testing day . 6 . The patient , patient 's parent ( ) , legally authorize guardian ( ) must voluntarily sign Institutional Review Board / Independent Ethics Committeeapproved inform consent form relevant aspect study explain discussed patient . The guardian ' consent must obtain . 1 . The patient clinically significant nonHunter syndromerelated CNS involvement judge Investigator likely interfere accurate administration interpretation protocol assessment . 2 . The patient IQ ≥78 3 . The patient CNS shunt . 4 . The patient experience infusionrelated anaphylactoid event evidence consistent severe adverse event related treatment Elaprase , Investigator 's opinion , may pose unnecessary risk patient . 5 . The patient know suspected hypersensitivity anesthesia think unacceptably high risk anesthesia due compromise airways condition 6 . The patient history complication previous lumbar puncture technical challenge conduct lumbar puncture potential risk would exceed possible benefit patient . 7 . The patient patient 's family history neuroleptic malignant syndrome , malignant hyperthermia , anesthesiarelated concern . 8 . The patient history poorly control seizure disorder . 9 . The patient significant medical psychiatric comorbidity ( y ) might affect study data confound integrity study result . 10 . The patient currently receive chronic psychotropic therapy ( e.g. , neuroleptic , benzodiazepine , antidepressant , anticonvulsant , stimulant , etc . ) Investigator 's opinion would likely affect neurocognitive assessment . Intermittent use select short halflife agent ( benzodiazepine , sedative , etc . ) may permit long 5 halflives last drug administer studyrelated procedure include neurocognitive assessment . 11 . The patient receive treatment investigational drug device within 30 day prior study entry . 12 . The patient receive cord blood bone marrow transplant time , receive blood product transfusion within 90 day prior Screening . 13 . The patient unable comply protocol , ( e.g. , significant hearing vision impairment , clinically relevant medical condition make implementation protocol difficult , unstable social situation , know clinically significant psychiatric/behavioral instability , unable return safety evaluation , otherwise unlikely complete study ) , determine Investigator . 14 . The patient skeletomuscular/spinal abnormality contraindication surgical implantation IDDD . 15 . The patient open CSF pressure upon lumbar puncture exceed 30 cm H2O ( water ) .</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>hunter syndrome</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>Mucopolysaccharidosis ( MPS ) II</keyword>
	<keyword>Mucopolysaccharidosis ( MPS ) 2</keyword>
	<keyword>Mucopolysaccharidosis ( MPS ) 2</keyword>
	<keyword>Mucopolysaccharidosis ( mp ) ii</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>mp symptom</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>ert treatment</keyword>
	<keyword>elaprase</keyword>
	<keyword>idursulfase</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>mp society</keyword>
</DOC>